Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Suren N. Sehgal"'
Autor:
John F. Dunne, Suren N. Sehgal, Rakesh Sindhi, Jan Allaert, Perry D. Haaland, Daiva Gladding, Bruce Koppelman
Publikováno v:
Journal of Immunological Methods. 272:257-272
Background : In mitogen-stimulated lymphocyte responses (sLR), cytokines and cell-surface receptors in peripheral human blood lymphocytes (PBL) are sensitive to cyclosporine (CsA), and can predict its in vivo effect with pharmacodynamic (PD) modeling
Autor:
Jaan Peets, Pierre Daloze, Junzheng Peng, Hongyu Luo, Dasheng Xu, Martine Loubeau, Ihor Bekersky, Suren N. Sehgal, Jiangping Wu, Shijie Qi, Minh Diem Vu, Xiaochun Wan, Huifang Chen, William E. Fitzsimmons
Publikováno v:
Transplantation. :1555-1561
Background. In nonprimates, organ allografts are often not rejected after withdrawal of immunosuppression.In this study, we examined whether such a phenomenon also occurs in primates. Methods. Vervet monkeys were transplanted with renal allografts an
Autor:
Suren N. Sehgal, Jiangping Wu, Dasheng Xu, Jaan Peets, Junzheng Peng, Huifang Chen, William E. Fitzsimmons, Shijie Qi, Minh Diem Vu, Pierre Daloze, Ihor Bekersky
Publikováno v:
Transplantation. 69:1275-1283
Background. Our previous studies confirmed that tacrolimus (FK506) and sirolimus [rapamycin (RAPA)], in combination, are not antagonistic but are synergistic in the prolongation of heart and small bowel grafts in the rodent. The aim of this study was
Autor:
Jonathan S. Jaffe, Gilbert J. Burckart, Emily Paulling, Robert Livingston, Rakesh Sindhi, John McMichael, Mariano F. LaVia, Laura A. Sindhi, Suren N. Sehgal, Susan Shaw
Publikováno v:
Transplantation. 69:432-436
Background, Clinically, cyclosporine (CSA, Neoral) is titrated to concentrations, and not to pharmacological effect. Methods. Intracellular interleukin- (IL) 2 was measured in phorbol myristic acid-ionomycin-stimulated peripheral lymphocytes by flow
Autor:
Pierre Daloze, Huifang Chen, Bernard Leduc, Jiangping Wu, Suren N. Sehgal, Minh Diem Vu, Shijie Qi, Junzheng Peng, Dasheng Xu
Publikováno v:
Transplantation. 66:1575-1580
Background. The effect of mycophenolate mofetil (MMF) and sirolimus (rapamycin, RAPA) mono- and combination-therapy was examined in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejecti
Autor:
Suren N. Sehgal
Publikováno v:
Clinical Biochemistry. 31:335-340
Objective: Rapamune is a novel immunosuppressive agent in Phase III clinical trial in renal transplantation. Its unique mechanism of action has created great interest in its use as a biochemical probe of signal transduction pathways that has provided
Autor:
Louis Dumont, Suren N. Sehgal, Shijie Qi, Pierre Daloze, Dasheng Xu, Stephan Busque, Huifang Chen, William E. Fitzsimmons, Jiangping Wu, Minh Diem Vu
Publikováno v:
Transplantation. 64:1853-1856
Combined use of tacrolimus (FK506) with sirolimus (rapamycin [RAPA]) was examined in a model of vascularized heart allograft in the rat. For prevention of acute rejection, three different combinations of low doses of FK506 and RAPA from day 1 up to d
Autor:
Patricia A. Taylor, Daniel A. Vallera, Suren N. Sehgal, Angela Panoskaltsis-Mortari, Bruce R. Blazar
Publikováno v:
Blood. 87:4001-4009
Rapamycin (RAPA) has been shown to be a highly effective means of reducing the lethality of graft-versus-host disease (GVHD) in B10.BR recipients of allogeneic C57BL/6 donor cells. RAPA-treated mice had no clinical (e.g., weight loss, diarrhea, letha
Autor:
Suren N. Sehgal, Steven J. Soldin, Roger L. Boeckx, David W. Holt, Barry D. Kahan, Randall W. Yatscoff, Kimberly L. Napoli, Calvin R. Stiller, Donald F. LeGatt
Publikováno v:
Therapeutic Drug Monitoring. 17:676-680
Publikováno v:
Current Opinion in Nephrology and Hypertension. 4:482-487
Rapamycin is a novel immunosuppressive agent that is undergoing clinical trials for use in allograft rejection therapy. This paper reviews its in-vitro biological properties, the current state of knowledge concerning its mechanism of action, and its